search
Back to results

Brain Response Associated With Parent-based Treatment for Childhood Anxiety Disorders

Primary Purpose

Anxiety Disorder of Childhood, Separation Anxiety Disorder of Childhood, Social Anxiety Disorder of Childhood

Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Supportive Parenting for Anxious Childhood Emotions
Parent Educational Support
Cognitive-Behavioral Therapy
Sponsored by
Yale University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Anxiety Disorder of Childhood focused on measuring anxiety disorders

Eligibility Criteria

6 Years - 12 Years (Child)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Prepubertal
  • Clinical diagnosis of primary anxiety disorder
  • Must not have another mental illness more impairing than the most impairing anxiety disorder
  • IQ of at least 80.

Exclusion Criteria:

  • Neurological disorders (including seizures)
  • Organic mental disorders, psychotic disorders, or pervasive developmental disorders
  • High likelihood of hurting themselves or others
  • Current psychosocial or psychopharmacological treatment
  • History of neurological illness or head injury with loss of consciousness > 5 minutes
  • Vision or physical disability that interferes with seeing stimuli presented briefly on computer screen and/or clicking a mouse button rapidly and repeatedly
  • Contraindications for MRI scanning (e.g., metal implants, pacemakers, braces, claustrophobia, pregnancy, weight > 250 pounds).

Sites / Locations

  • Yale University Child Study CenterRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Supportive Parenting for Anxious Childhood Emotions

Parent Educational Support or CBT

Arm Description

Parent-based treatment for childhood anxiety disorders

Parent-based intervention for childhood anxiety disorders (phase 1) or child based treatment for childhood anxiety disorders (phase 2)

Outcomes

Primary Outcome Measures

Pediatric Anxiety Rating Scale (PARS)
The PARS is a clinician-administered measure of anxiety severity in children and adolescents. Total scores on PARS are used as indicator of anxiety severity. Total scores range from 0-35, with higher scores indicating more severe anxiety.

Secondary Outcome Measures

Multimodal Anxiety Scale for Children (MASC)
The MASC is a self-report measure of anxiety severity, completed by children and parents separately. MASC generates a total anxiety score and several sub scales: Total scores: range from 0-150 Separation/Phobias scores: range from 0-27 Generalized anxiety scores: range from 0-30 Social anxiety scores: range from 0-27 Obsessive-compulsive symptom scores: 0-50 Physical symptoms scores: 0-60 For Total score and all sub-scales, higher scores indicate more severe anxiety.

Full Information

First Posted
June 29, 2018
Last Updated
May 30, 2023
Sponsor
Yale University
search

1. Study Identification

Unique Protocol Identification Number
NCT03585010
Brief Title
Brain Response Associated With Parent-based Treatment for Childhood Anxiety Disorders
Official Title
Brain Response Associated With Parent-based Treatment for Childhood Anxiety Disorders
Study Type
Interventional

2. Study Status

Record Verification Date
May 2023
Overall Recruitment Status
Recruiting
Study Start Date
September 1, 2018 (Actual)
Primary Completion Date
July 31, 2023 (Anticipated)
Study Completion Date
December 31, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Yale University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This study aims to investigate whether a parent-based treatment for childhood anxiety disorders engages child brain circuitry implicated in children's reliance on parents to reduce anxiety (R61), and whether change in child brain circuitry is associated with reduction in child anxiety (R33).
Detailed Description
Specific Aims: Anxiety disorders impact up to one-third of children, cause tremendous suffering, increase risk for psychiatric and medical morbidity, impair school and social functioning, and cost billions of dollars each year. Data consistently show that child anxiety is characterized by amygdala hyperactivity and deficits in prefrontal control of the amygdala. Emerging data link these disruptions to anxious children's over-reliance on parents for amygdala-medial prefrontal cortex (mPFC) engagement and anxiety reduction. In the first phase of this study we aim to demonstrate that an entirely parent-based psychosocial treatment with no child involvement, Supportive Parenting for Anxious Childhood Emotions (SPACE), engages an amygdala-mPFC target in anxious children, lessening child reliance on parents to reduce amygdala reactivity. Cross-species neurobiological evidence indicates that parental presence reduces amygdala reactivity and activates the mPFC to reduce offspring anxiety. In humans we recently demonstrated parental presence increases functional connectivity between their child's mPFC and amygdala, reducing the child's amygdala reactivity and anxiety. In a healthy sample, parental engagement of child amygdala-mPFC connectivity was linked to the child's reliance on parents for help with anxiety. Data from clinically anxious children likewise show parental presence engages child mPFC, and data we collected since our previous submission demonstrate that parental presence reduces amygdala reactivity in clinically anxious children. Offspring's natural reliance on parents for anxiety reduction is magnified in clinically anxious children. Parents become deeply enmeshed in their child's symptoms through the process of family accommodation, defined as change in parents' behavior to help the child avoid or alleviate anxiety. In clinically anxious children, 90% report depending on parents to reduce their anxiety, and 97% of parents report accommodating their anxious child's symptoms. These cross-generational patterns of parental entanglement in their child's anxiety symptoms contribute to the immense burden, distress, and costs of pediatric anxiety (e.g., parents missing work to be with their anxious child). Anxious children's reliance on parents for anxiety reduction may disrupt the child's ability to independently reduce amygdala reactivity and anxiety. We developed SPACE to translate these neurobiological and clinical research findings into a manualized parent-based treatment focused on reducing family accommodation in parents of anxious children. Preliminary data from a randomized clinical trial show that after 12 weeks of parents receiving SPACE (N=29), with no therapist-child contact, family accommodation and child anxiety were significantly reduced. We propose that SPACE engages anxious children's amygdala-mPFC circuitry, lessening their reliance on parents to reduce amygdala reactivity. The first phase of the study will examine clinically anxious children's (N=90, 7-10 yrs) amygdala-mPFC response to fear faces when (A) the child's parent is beside them holding their hand during the fMRI scan (Parent-Present), and (B) the child is alone during the scan (Parent-Absent) (within-subjects design). Children with primary separation, social, or generalized anxiety disorder diagnoses, the most common childhood anxiety disorders, will serve as participants. Children will complete Parent-Present and Parent-Absent scans PRE- and POST-SPACE, or PRE- and POST-Parent Educational Support (PES), the comparator treatment that controls for treatment duration and therapist-parent contact. We expect SPACE will lessen child reliance on parental presence to engage amygdala-mPFC circuitry and reduce child amygdala reactivity. Aim 1: Demonstrate SPACE lessens children's reliance on parents to reduce amygdala reactivity (target engagement). Hyp 1: Child reliance on parental presence to reduce amygdala reactivity, (i.e., the difference between child amygdala reactivity in the Parent-Present and Parent-Absent scan), will decrease significantly from PRE- to POST-SPACE, as compared with PRE- to POST-PES. If Hyp 1 is confirmed we will proceed to the the second phase of the study. The second phase of the study will be performed to re-demonstrate target engagement in SPACE, compared to cognitive-behavioral therapy (CBT); demonstrate target engagement is associated with symptom reduction in SPACE; and demonstrate SPACE's acceptability/feasibility. The second phase will enroll 136 clinically anxious children (7-10 yrs), randomly assigned to SPACE or CBT. Aim 1: Re-demonstrate target engagement in SPACE. Hyp 1: Child reliance on parental presence to reduce amygdala reactivity will decrease significantly from PRE- to POST-SPACE, as compared with PRE- to POST-CBT. Aim 2: Demonstrate target engagement is associated with symptom reduction in SPACE. Hyp 2: Reduction in child anxiety from PRE- to POST-SPACE will be significantly associated with reduction in child reliance on parental presence to reduce amygdala reactivity. Aim 3: Establish acceptability and feasibility of SPACE. Hyp 3: SPACE will be acceptable and feasible to administer, and comparable to CBT. The second phase will also provide insight into the relative efficacy of SPACE, to inform future research and development of SPACE. This study has the potential to provide groundbreaking results, with major public health impact, on how parent-based treatments can target disrupted neurobiological processes in children with psychopathology. These novel data will inform decision-making about a large-scale study (R01) to confirm the efficacy of SPACE and examine personalized treatment strategies.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Anxiety Disorder of Childhood, Separation Anxiety Disorder of Childhood, Social Anxiety Disorder of Childhood, Generalized Anxiety Disorder
Keywords
anxiety disorders

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Masking Description
Assessments will conducted by independent evaluators, blind to treatment condition.
Allocation
Randomized
Enrollment
226 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Supportive Parenting for Anxious Childhood Emotions
Arm Type
Experimental
Arm Description
Parent-based treatment for childhood anxiety disorders
Arm Title
Parent Educational Support or CBT
Arm Type
Active Comparator
Arm Description
Parent-based intervention for childhood anxiety disorders (phase 1) or child based treatment for childhood anxiety disorders (phase 2)
Intervention Type
Behavioral
Intervention Name(s)
Supportive Parenting for Anxious Childhood Emotions
Intervention Description
12 sessions with parents
Intervention Type
Behavioral
Intervention Name(s)
Parent Educational Support
Intervention Description
12 sessions with parents
Intervention Type
Behavioral
Intervention Name(s)
Cognitive-Behavioral Therapy
Intervention Description
12 sessions with child
Primary Outcome Measure Information:
Title
Pediatric Anxiety Rating Scale (PARS)
Description
The PARS is a clinician-administered measure of anxiety severity in children and adolescents. Total scores on PARS are used as indicator of anxiety severity. Total scores range from 0-35, with higher scores indicating more severe anxiety.
Time Frame
12 weeks
Secondary Outcome Measure Information:
Title
Multimodal Anxiety Scale for Children (MASC)
Description
The MASC is a self-report measure of anxiety severity, completed by children and parents separately. MASC generates a total anxiety score and several sub scales: Total scores: range from 0-150 Separation/Phobias scores: range from 0-27 Generalized anxiety scores: range from 0-30 Social anxiety scores: range from 0-27 Obsessive-compulsive symptom scores: 0-50 Physical symptoms scores: 0-60 For Total score and all sub-scales, higher scores indicate more severe anxiety.
Time Frame
12 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
6 Years
Maximum Age & Unit of Time
12 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Prepubertal Clinical diagnosis of primary anxiety disorder Must not have another mental illness more impairing than the most impairing anxiety disorder IQ of at least 80. Exclusion Criteria: Neurological disorders (including seizures) Organic mental disorders, psychotic disorders, or pervasive developmental disorders High likelihood of hurting themselves or others Current psychosocial or psychopharmacological treatment History of neurological illness or head injury with loss of consciousness > 5 minutes Vision or physical disability that interferes with seeing stimuli presented briefly on computer screen and/or clicking a mouse button rapidly and repeatedly Contraindications for MRI scanning (e.g., metal implants, pacemakers, braces, claustrophobia, pregnancy, weight > 250 pounds).
Facility Information:
Facility Name
Yale University Child Study Center
City
New Haven
State/Province
Connecticut
ZIP/Postal Code
06519
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Eli R Lebowitz, Ph.D.
Phone
203-785-7905
Email
eli.lebowitz@yale.edu

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Deidentified individual participant data for primary and secondary measures will be made available
IPD Sharing Time Frame
Data will be available six months after study completion
IPD Sharing Access Criteria
Data access requests will be reviewed by review panel and requestors will sign a Data Access Agreement

Learn more about this trial

Brain Response Associated With Parent-based Treatment for Childhood Anxiety Disorders

We'll reach out to this number within 24 hrs